Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Glandular Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Glandular Cell Neoplasm

Cancer Family

Glandular Cell Neoplasm

CI-CAN-00000188Explore in graph →

Non-malignant2,825 active trials43 approved drugs426 evidence items

NCIt: C7132

Overview
Statistics
Survival
Genomics166
Variants & evidence426
Drugs106
Trials10211
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (384)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 126–150 of 384 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.
· JCO Precis Oncol · 2022 · PMID 35939768 · validated civic_curation pubmed
Analysis of clinicopathologic features and expression of NR4A3 in sinonasal acinic cell carcinoma.
· Mod Pathol · 2022 · PMID 34873305 · validated civic_curation pubmed
LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors.
· Transl Lung Cancer Res · 2023 · PMID 37057124 · validated civic_curation pubmed
Potential Resistance to Oxaliplatin-Based Regimens in Gastric Cancer Patients with ERBB2 R678Q Mutation: Evidence from a National Genomic Database.
· Curr Issues Mol Biol · 2025 · PMID 40699829 · validated civic_curation pubmed
Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations.
· J Clin Oncol · 2025 · PMID 39413348 · validated civic_curation pubmed
PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.
· Oncology · 2015 · PMID 25300346 · validated civic_curation pubmed
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.

Showing 126–150 of 384 publications

← Previous
1
…
5
6
7
…
16
Next →

· Clin Breast Cancer · 2015 · PMID 25537159 · validated civic_curation pubmed

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.

· Br J Cancer · 2012 · PMID 22596232 · validated civic_curation pubmed

Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer.

· Int J Cancer · 2012 · PMID 22422354 · validated civic_curation pubmed

CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer.

· Anticancer Res · 2010 · PMID 20651371 · validated civic_curation pubmed

Mutation and methylation analysis of TP53 in adrenal carcinogenesis.

· Eur J Surg Oncol · 2005 · PMID 15922892 · validated civic_curation pubmed

Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes.

· Oncotarget · 2016 · PMID 26872370 · validated civic_curation pubmed

PSMB8 and PBK as potential gastric cancer subtype-specific biomarkers associated with prognosis.

· Oncotarget · 2016 · PMID 26894977 · validated civic_curation pubmed

High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.

· Oncotarget · 2016 · PMID 26950277 · validated civic_curation pubmed

Nuclear heat shock protein 110 expression is associated with poor prognosis and chemotherapy resistance in gastric cancer.

· Oncotarget · 2016 · PMID 26943774 · validated civic_curation pubmed

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

· Cancer Cell · 2007 · PMID 17936563 · validated civic_curation pubmed

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

· Clin Cancer Res · 2014 · PMID 25294897 · validated civic_curation pubmed

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

· Clin Cancer Res · 2013 · PMID 23881929 · validated civic_curation pubmed

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.

· J Thorac Oncol · 2016 · PMID 26773740 · validated civic_curation pubmed

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.

· Nat Commun · 2016 · PMID 27302369 · validated civic_curation pubmed

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).

· PLoS One · 2016 · PMID 27032107 · validated civic_curation pubmed

Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization.

· Mol Cell Endocrinol · 2015 · PMID 25448848 · validated civic_curation pubmed

Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases.

· Mod Pathol · 2019 · PMID 30980040 · validated civic_curation pubmed

SMARCB1/INI1 inactivation in renal medullary carcinoma.

· Histopathology · 2012 · PMID 22686875 · validated civic_curation pubmed

Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.

· Cancer Biomark · 2017 · PMID 28269754 · validated civic_curation pubmed